Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 25, 2010

View Archived Issues

Medivir identifies NS5B polymerase inhibitors for HCV infection

HIV-targeting gene therapy shows prolonged viremia control in phase I/II trial

HCV RNA synthesis inhibitor ATI-0810 exhibits favorable safety and pharmacokinetics in vivo

Novel focal adhesion kinase inhibitors discovered at AstraZeneca

Roche identifies new inhibitors of Bruton tyrosine kinase BTK

Takeda discloses new renin inhibitors for hypertension

Hutchison MediPharma presents novel epidermal growth factor receptor inhibitors

Phase III NOV-002 trial in NSCLC fails to meet primary endpoint

Enzon treats first pediatric cancer patient in phase I PEG-SN38 trial

New fusion inhibitor shows potent antiviral activity in wild-type and RTI-resistant HIV strains

DIVA 01 trial data indicate good penetration of raltegravir in genital tract of HIV-infected women

HSP90 inhibitor STA-9090 targets oncogenic functions of Wilms tumor protein in AML cells

FDA recommends approval of rifaximin for management of hepatic encephalopathy

Eisai launches Revovir in the Philippines for chronic hepatitis B

FDA accepts Arena Pharmaceuticals' lorcaserin NDA for filing

Basilea enters into global partnership with Astellas for isavuconazole

Five Prime Therapeutics reports milestone for immunology-related therapeutic program

Shire receives FDA fast track designation for Replagal

FDA approves Prevnar 13 for prevention of pneumococcal disease in infants and children

Evotec and Cubist extend and expand research agreement

GSK criticizes Senate Committee on Finance's report on Avandia

U.K. approval granted for HealthLinx's OvPlex trial in ovarian cancer

Kyowa Hakko Kirin submits NDA in Japan for Abstral in breakthrough cancer pain

Cleveland BioLabs responds to Department of Defense RFP for CBLB-502

Anadys reports preliminary phase II results on ANA-598/SOC therapy for hepatitis C

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
EASL spotlight: TUNE-401 advances epigenetic silencing in HBV
BioWorld
Several presentations at EASL highlight a new generation of therapies coming into view, with the work from Tune Therapeutics Inc. standing out as one of the most...